Lundbeck wraps Chelsea tender offer; PA court tosses $28M pricing award against BMS; Pfizer wins new Prevenar 13 nod in Japan;

@FiercePharma: Top-read on FP this weekend: Why does #Sovaldi cost $84,000? Gilead being pressed hard for an answer. Story | Follow @FiercePharma

@TracyStaton: ICYMI, the latest in the #Sovaldi pricing squabble: Congress wants to get involved. More | Follow @TracyStaton

@EricPFierce: How much are the big dogs of Big Pharma paid? A lot. See the top 15 highest paid CEOs here. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Italian officials probe Novartis for possible flu vaccine pricing fraud. News | Follow @CarlyHFierce

> Denmark's Lundbeck wrapped up its tender offer for Chelsea Therapeutics, which will bring along its recently FDA-approved orphan drug Northera. Report

> The Pennsylvania Supreme Court tossed out a $28 million award against Bristol-Myers Squibb ($BMY) in a drug-pricing dispute. Report

> Pfizer ($PFE) won the nod for broader use of its Prevnar 13 vaccine in Japan, in adults 65 years and older, a key market in a country with an aging population. Report

> Pfizer ($PFE) lost a fight to exclude its Depo Testosterone product from a consolidation of all lawsuits over testosterone treatments. Report

> Regulators are planning to overhaul India's drug pricing structure, and they're looking at pricing models in other countries for ideas. Report

Medical Device News

@FierceMedDev: Apple, Google stalk wearable med tech with glucose monitoring up first. Feature | Follow @FierceMedDev

@StacyALawrence: AbbVie says Shire has spurned three buyout offers, won't rule out new bid. Story from Friday | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: Medtronic reveals cyberattack and lost patient data in latest regulatory filing. More | Follow @EmilyWFierce

> In test of FDA guidelines, medical mobile app Abriiz escapes scrutiny. News

> FDA to stop regulating some medical device software. More

Biotech News

@FierceBiotech: Roche partners with Versant on a new build-to-sell biotech on MS. More | Follow @FierceBiotech

@JohnCFierce: FDA review red-flags AstraZeneca's case for ovarian cancer drug olaparib. Story | Follow @JohnCFierce

@DamianFierce: Amazing first line of a BIO 2014 email: "As you have probably heard Steve Burrill is unable to attend BIO this year." Yeah, I heard. | Follow @DamianFierce

@EmilyMFierce: Stem cell treatment for horses to be tried in humans. Story via BBC News | Follow @EmilyMFierce

> Beaten by rivals, Boehringer surrenders in hep C contest. More

> John Carroll wins the European Mediscience 'Commentator of the Year' award. Publisher's note

> Gelesis declares a weight-loss victory, but a critic pans new therapy. Story

CRO News

> Teva settles with Catalent, Perrigo in inhaler patent suit. Item

> Parexel rolls out new eClinical tech to speed up study start-up. Story

> Simbec buys its way into late-stage R&D with Orion deal. Article

> Japanese CRO taps BBK for a U.S. joint venture. News

> Quintiles partners up to flex its commercial muscles. More

> BioClinica dives into adaptive trials with latest buy. Report

Biotech IT News

> Survey: Biopharma still reliant on paper, email for sharing TMFs. Item

> USC in talks to buy or affiliate with Scripps. Story

> AstraZeneca opens up compound library to select academics. More

> FDA's long-awaited Twitter guidance gives biopharma certainty and constraints. Article

> Big Pharma consortium adds redaction of trial information to list of initiatives. News

> Tech vendors flock to DIA to show off new software. Report

And Finally... A federal judge upheld New York City's policy of barring unimmunized children from school when another student is ill with a vaccine-preventable disease. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.